– USA, MA – Checkmate Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused upon activation of innate immunity to treat advanced cancer, today announced the addition of Keith T. Flaherty, M.D. to its Board of Directors.
“We welcome Dr. Flaherty to our Board of Directors and are looking forward to his guidance during the exciting times ahead. Keith’s experiences both as a clinical researcher developing innovative oncology products and as a Board member of development-stage oncology companies will be tremendously helpful as we continue to advance Checkmate’s mission to provide transformative new treatment options for oncology patients,” commented Barry Labinger, President and CEO of Checkmate Pharmaceuticals.
About Dr Keith Flaherty
Dr. Flaherty is a Professor of Medicine at Harvard Medical School, Associate Physician of Medicine, Hematology/Oncology at Massachusetts General Hospital, Director of Clinical Research, Massachusetts General Hospital Cancer Center, and Editor-in-Chief of Clinical Cancer Research. He co-founded and served on the Board of Directors of Loxo Oncology, Inc. until its acquisition by Eli Lilly and Company, and he currently serves on the Board of Directors of Clovis Oncology, Inc. (NASDAQ: CLVS). Dr. Flaherty has a Bachelor of Science from Yale University and a medical degree from Johns Hopkins University. Dr. Flaherty trained in internal medicine at Brigham and Women’s Hospital and completed a medical oncology fellowship at the University of Pennsylvania.
“I am excited to join the Checkmate Board at a critical time, as the company advances toward definitive trials to confirm the benefit of CMP-001, having established proof-of-concept that the agent can overcome resistance to PD-1 antibody therapy in melanoma,” commented Dr. Flaherty. “I believe CMP-001 offers promise to enhance immunotherapy for patients with a variety of types of cancer.”
Checkmate Pharmaceuticals is a clinical stage company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies and to provide new treatment options for patients and their healthcare providers. Checkmate’s lead product candidate, CMP-001, is an investigational cancer immunotherapeutic that has been shown to reverse resistance to PD-1 therapy in some patients.
Checkmate is a privately held company headquartered in Cambridge, MA.
For more information : https://checkmatepharma.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.